Evidence map›Paper›PMID 35282090›Full record

ArticleAnnals of translational medicine2022

Preliminary evaluation of a new initiative to centralize colorectal cancer care during the COVID-19 epidemic in Shanghai, China: a retrospective study.

Rui Liu, Xuejing Yu, Xueyun Zeng, Zheng Wang, Danqing Zhou, Zhongchen Liu, Feng Liu, Chengle Zhuang, Ying Zhuang, Ji Zhang and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of translational medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Rui Liu *Tongji University Cancer Center, Shanghai Tenth People's Hospital of Tongji University, Shanghai, China.
Xuejing Yu *Tongji University Cancer Center, Shanghai Tenth People's Hospital of Tongji University, Shanghai, China.
Xueyun Zeng *Tongji University Cancer Center, Shanghai Tenth People's Hospital of Tongji University, Shanghai, China.
Zheng WangColorectal Cancer Center, Shanghai Tenth People's Hospital of Tongji University, Shanghai, China.
Danqing ZhouTongji University Cancer Center, Shanghai Tenth People's Hospital of Tongji University, Shanghai, China.
Zhongchen LiuColorectal Cancer Center, Shanghai Tenth People's Hospital of Tongji University, Shanghai, China.
Feng LiuColorectal Cancer Center, Shanghai Tenth People's Hospital of Tongji University, Shanghai, China.
Chengle ZhuangColorectal Cancer Center, Shanghai Tenth People's Hospital of Tongji University, Shanghai, China.
Ying ZhuangColorectal Cancer Center, Shanghai Tenth People's Hospital of Tongji University, Shanghai, China.
Ji ZhangMedical Service Section, Shanghai Tenth People's Hospital of Tongji University, Shanghai, China.
Peiqin NiuMedical Service Section, Shanghai Tenth People's Hospital of Tongji University, Shanghai, China.
Ben YanDepartment of Infrastructure, Shanghai Tenth People's Hospital of Tongji University, Shanghai, China.
Rui ZhiDepartment of Infrastructure, Shanghai Tenth People's Hospital of Tongji University, Shanghai, China.
Jiyu LiTongji University Cancer Center, Shanghai Tenth People's Hospital of Tongji University, Shanghai, China.
Jiaoling HuangSchool of Public Health, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Huanlong QinTongji University Cancer Center, Shanghai Tenth People's Hospital of Tongji University, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: A novel colorectal cancer center (CCC) was developed in the Shanghai Tenth People's hospital of Tongji University during the COVID-19 epidemic. In this study, we aimed to evaluate the CCC model in terms of three aspects. Methods: This retrospective study used data from the Shanghai Tenth People's hospital patient databases. The research hypothesis was that the CCC reduces preoperative waiting time (PWT), length of hospital stay (LOS), and costs of hospitalization, without reducing the quality of surgery. Thus, we compared the time, cost, and quality between March 1 to December 31, 2019, and March 1 to December 31, 2020. Descriptive and inferential analyses of patient demographic characteristics, time, postoperative outcomes, and inpatient costs were conducted. Results: A total of 965 hospitalizations for colorectal cancer (CRC) were identified-415 in 2019 and 550 in 2020. In the CCC, PWT declined by 26.2 hours (P<0.01). Patients in the CCC express group only needed to wait for 24.5 hours before undergoing surgery, with a shorter LOS than the normal group (P<0.01). None of the patients had any symptoms of COVID-19 or were high-risk COVID-19 contacts, and the incidence of immediate postoperative complications was low. The mean total inpatient cost (TIC) for all patients with CRC was 78,309.824 Chinese Yuan in 2020, which was slightly lower than that in 2019. Conclusions: This study found that the centralized management model for CRC care could help patients save the PWT, LOS and costs of hospitalization during the COVID-19 epidemic.

Indexed as

Colorectal cancer (CRC)colorectal surgerycoronavirus disease 2019 (COVID-19)health economicsintegrated care

Identifiers

PMID35282090
PMCPMC8848422

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.